Establish Diagnostic Models Based on Portal Venous Blood for Pancreatic Cancer
ConditionDiagnoses Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorChanghai Hospital
About this trial
Explore new markers based on portal venous blood sampling to establish novel diagnostic models for identification of malignant pancreatic mass.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
age 18-75 years,male or female
diagnosis or suspection of solid pancreatic mass based on previous imaging examination (ultrasonography, CT or MRI)
lesion diameter larger than 1 cm
signed informed consent letter
Disqualifiers
pregnant female
Pancreatic cystic lesions
Anticoagulant/antiplatelet therapy cannot be suspended
unable or refuse to provide informed consent
Trial population
All patients who meet the inclusion criteria, but not the exclusion criteria, will be included in current study. Pancreatic mass tissue samples, portal venous blood, and periferal blood will be collected for identification of potential markers for diagnosis of malignant pancreatic cancer.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Endoscopic Ultrasound (EUS), Fine Needle Aspiration
Diagnostic testEndoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations
Treatment groups
300 Participants
are divided into 2 treatment groupsGroup A: pancreatic mass diagnosed benign1 intervention
Group B: pancreatic mass diagnosed malignant1 intervention
Trial outcomes
Primary outcomes
1
Status of survival
To varify if the patients died becaused of malignant pancreatic cancer.
Time frame
through study completion, an average of 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov